Tenascin-C as a potential biomarker and therapeutic target for esophageal squamous cell carcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tenascin-C (TNC) is highly expressed in esophageal squamous cell carcinoma (ESCC). Targeting TNC shows therapeutic potential, improving prognosis prediction and enhancing sensitivity to targeted therapies.
Area Of Science
- Oncology
- Molecular Biology
- Biomarker Discovery
Background
- Esophageal squamous cell carcinoma (ESCC) poses a significant health challenge.
- Tenascin-C (TNC) is implicated in tumor progression but its prognostic and therapeutic roles in ESCC require further elucidation.
Purpose Of The Study
- To develop a prognostic model for ESCC patients using TNC expression and clinicopathological features.
- To investigate the therapeutic implications of inhibiting TNC in ESCC.
Main Methods
- Immunohistochemistry (IHC) to quantify TNC expression in ESCC tissues.
- Cox regression and nomogram construction for prognostic modeling.
- In vitro and in vivo studies assessing TNC knockdown effects.
- RNA-sequencing and GSEA to identify TNC-regulated pathways.
- Evaluation of combination therapy with TNC inhibition and small-molecule inhibitors.
Main Results
- TNC was significantly overexpressed in ESCC tissues compared to normal tissues (48.77% vs 2%).
- A nomogram integrating TNC expression, pT stage, and lymph node metastasis demonstrated strong prognostic performance.
- TNC knockdown suppressed ESCC cell proliferation and xenograft growth, downregulating key tumor growth pathways.
- TNC inhibition potentiated the efficacy of inhibitors targeting EGFR, PI3K-Akt, Ras, and MAPK pathways.
Conclusions
- The developed nomogram serves as a promising tool for ESCC survival prediction.
- Reducing TNC expression enhances ESCC cell sensitivity to EGFR and downstream pathway inhibitors, suggesting a novel combination therapy strategy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor tyrosine kinases:
Receptor tyrosine kinases (RTKs) phosphorylate specific tyrosines on the signaling proteins. RTKs include various growth factor receptors,...